GGrantIndex
Sort

51,593 grants matching hepatitis

University of Washington Vaccine and Treatment Evaluation Unit

$1,863,350
Anna Wald · University Of Washington · UM1 · FY2023 · AI

A-Z Clinical Trials Unit

$1,862,682
Paul A. Goepfert · University Of Alabama At Birmingham · UM1 · FY2023 · AI

ADULT AIDS CLINICAL TRIALS UNIT

$1,862,162
University Of California San Francisco · U01 · FY2002 · AI

Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplication

$1,861,737
Ian Matthias Sanne · Wits Health Consortium (Pty), Ltd · UM1 · FY2024 · AI

AIDS CLINICAL TRIALS GROUP - ACTU

$1,860,322
University Of Cincinnati · U01 · FY2002 · AI

AIDS CLINICAL TRIALS GROUP - ACTU

$1,860,320
University Of Cincinnati · U01 · FY2005 · AI

GENETICS OF ATHEROSCLEROSIS--ROLE OF INSULIN RESISTANCE

$1,859,298
University Of California Los Angeles · P01 · FY2003 · HL

Molecular Mechanisms of Pathogenesis of Acute and Chronic Liver Diseases

$1,859,055
Patrizia Farci · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI

Chimpanzee Biomedical Research Program Limited Competition (U42)

$1,858,987
M. Babette Fontenot · University Of Louisiana At Lafayette · U42 · FY2012 · OD

Molecular Biology and Genetics of Human Tumor Viruses

$1,858,213
William M. Sugden · University Of Wisconsin-Madison · P01 · FY2011 · CA

TERT mRNA lipid nanoparticles to extend telomeres to treat alcoholic hepatitis

$1,858,106
John Ramunas · Rejuvenation Technologies, Inc. · R44 · FY2024 · AA

CENTER FOR ALCOHOLIC LIVER AND PANCREATIC INJURY

$1,856,997
University Of Southern California · P50 · FY2003 · AA

MOLECULAR BIOMARKERS FOR ENVIRONMENTAL TOXICANTS

$1,856,927
John D Groopman · Johns Hopkins University · P01 · FY2008 · ES

Studies of HIV infection and its contribution to the natural history and outcome

$1,855,718
Eric A Engels · Division Of Cancer Epidemiology And Genetics · ZIA · FY2025 · CA

Soluble epoxide hydrolase-regulated lipid signaling in Alzheimer’s disease

$1,855,051
Izumi Maezawa · University Of California At Davis · RF1 · FY2021 · AG

Entry and replication of positive-sense, RNA viruses

$1,850,932
Joseph Marcotrigiano · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI

A 3D biomimetic liver sinusoid construct for predicting physiology and toxicity

$1,850,825
D. Lansing Taylor · University Of Pittsburgh At Pittsburgh · UH3 · FY2015 · TR

Molecular Biology and Genetics of Human Tumor Viruses

$1,850,672
William M. Sugden · University Of Wisconsin-Madison · P01 · FY2012 · CA

New Therapies for Liver Fibrosis and Hyperproliferation in Alpha1-AT Deficiency

$1,848,657
David H Perlmutter · Washington University · P01 · FY2023 · DK

Functional Genomics and HCV-Associated Liver Disease

$1,848,035
Michael G Katze · University Of Washington · P30 · FY2010 · DA

Discovery of an Orexin-1 receptor antagonist for treatment of cocaine addiction and dependence

$1,847,427
Fiona Marshall · Heptares Therapeutics, Ltd · R01 · FY2015 · DA

Liver Lung Interactions in Lung Inflammation

$1,847,206
Vanderbilt University · P01 · FY2004 · HL

Molecular Biology and Genetics of Human Tumor Viruses

$1,846,989
William M. Sugden · University Of Wisconsin-Madison · P01 · FY2008 · CA

CURE CTU

$1,845,017
Stephen A Spector · University Of California, San Diego · UM1 · FY2025 · AI

Fully human recombinant therapeutic anti-vaccinia virus polyclonal antibody

$1,843,539
Soren Bregenholt · Symphogen A/S · U01 · FY2007 · AI